Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Arrowhead Pharma
(NQ:
ARWR
)
28.66
+0.47 (+1.67%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 29, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Arrowhead Pharma
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
April 01, 2024
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Pharmaceuticals Initiates Expanded Access Program for Plozasiran and Announces Upcoming Presentation of Clinical Data
March 25, 2024
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
7 Biotech Stocks to Buy as Sector Rotation Ramps Up
March 13, 2024
With digital innovation possibly getting overextended, now’s the time to consider biotech stocks for an incoming rotation.
Via
InvestorPlace
The 3 Most Undervalued Russell 2000 Stocks to Buy in March 2024
March 11, 2024
The Russell 2000 is up about 4% year to date, and could push higher, taking the most undervalued Russell 2000 stocks along for the ride.
Via
InvestorPlace
Cracking The Code: Understanding Analyst Reviews For Arrowhead Pharma
February 07, 2024
Via
Benzinga
Recap: Arrowhead Pharma Q1 Earnings
February 06, 2024
Via
Benzinga
Earnings Scheduled For February 6, 2024
February 06, 2024
Companies Reporting Before The Bell • BP (NYSE:BP) is projected to report quarterly earnings at $1.05 per share on revenue of $53.50 billion.
Via
Benzinga
EQT, Genie Energy And Other Big Stocks Moving Lower On Monday
March 11, 2024
U.S. stocks were lower, with the Dow Jones index falling more than 150 points on Monday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DM1 for Treatment of Type 1 Myotonic Dystrophy
March 08, 2024
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Pharmaceuticals to Participate in Upcoming March 2024 Conferences
March 04, 2024
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Cooper Companies Reports Upbeat Results, Joins Dell, NetApp, Tidewater And Other Big Stocks Moving Higher On Friday
March 01, 2024
U.S. stocks were higher, with the Nasdaq Composite gaining around 0.5% on Friday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
7 Oversold Russell 2000 Stocks to Add to Your February Buy List
February 25, 2024
Investors may want to jump into oversold Russell 2000 stocks. After a rough outing in 2023, many are starting to come back strong.
Via
InvestorPlace
Weight-Loss Drugs Have One Big Problem. These Drugmakers Are Taking It On.
February 23, 2024
Weight-loss drugs from Novo Nordisk and Eli Lilly lead to massive weight loss. But not all of that weight loss is healthy.
Via
Investor's Business Daily
7 Biotech Stocks Fighting America’s Deadliest Diseases
February 08, 2024
Although the human condition can be alarmingly frail at times, these groundbreaking biotech stocks are aiming to right the ship.
Via
InvestorPlace
12 Health Care Stocks Moving In Tuesday's After-Market Session
February 06, 2024
Via
Benzinga
Arrowhead Pharmaceuticals Reports Fiscal 2024 First Quarter Results
February 06, 2024
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
4 Analysts Assess Arrowhead Pharma: What You Need To Know
January 02, 2024
Via
Benzinga
What 4 Analyst Ratings Have To Say About Arrowhead Pharma
December 04, 2023
Via
Benzinga
Arrowhead Pharmaceuticals to Webcast Fiscal 2024 First Quarter Results
January 22, 2024
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Pharmaceuticals Closes Underwritten Offering with Gross Proceeds of $450.0 Million
January 05, 2024
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024
January 05, 2024
Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain.
Via
Investor's Business Daily
Lamb Weston Posts Upbeat Results, Joins Omega Therapeutics, Allstate And Other Big Stocks Moving Higher On Thursday
January 04, 2024
U.S. stocks traded mostly higher, with the Dow Jones index gaining around 150 points on Thursday. Shares of Lamb Weston Holdings, Inc. (NYSE: LW) rose during Thursday’s session following...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why SoFi Technologies Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
January 03, 2024
Shares of SoFi Technologies, Inc. (NASDAQ: SOFI) fell sharply during Wednesday’s session after Keefe, Bruyette & Woods downgraded rating on the stock.
Via
Benzinga
Why Arrowhead Pharmaceuticals Shares Are Moving
January 03, 2024
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) shares are trading higher by 5.4% to $32.68, gaining after initially falling, after the company priced an underwritten registered offering of about 15.79...
Via
Benzinga
TDCX Receives Preliminary Non-binding Proposal Letter, Joins Pure Storage, Dyne Therapeutics And Other Big Stocks Moving Higher On Wednesday
January 03, 2024
U.S. stocks traded lower, with the Nasdaq Composite falling around 150 points on Wednesday. Shares of TDCX Inc. (NYSE: TDCX) rose sharply during Wednesday’s session after it disclosed receiving a...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Arrowhead Pharmaceuticals Announces Pricing of $450.0 Million Underwritten Offering of Common Stock
January 03, 2024
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
December 29, 2023
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Top Biotech Picks For 2024: Piper Sandler Foresees Potential Sector Comeback
December 29, 2023
Piper Sandler sees potential turnaround for Biotech sector in 2024, identifies thee top stocks; Arrowhead, Legend Biotech & Alnylam Pharmaceuticals.
Via
Benzinga
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-CFB for Complement Mediated Kidney Disease
December 21, 2023
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
December 20, 2023
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.